Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance
Suellen Nicholson, Theo Karapanagiotidis, Arseniy Khvorov, Celia Douros, Francesca Mordant, Katherine Bond, Julian Druce, Deborah A Williamson, Damian Purcell, Sharon R Lewin, Sheena Sullivan, Kanta Subbarao, Mike Catton
OPEN FORUM INFECTIOUS DISEASES | OXFORD UNIV PRESS INC | Published : 2021
Background: Serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) complements nucleic acid tests for patient diagnosis and enables monitoring of population susceptibility to inform the coronavirus disease 2019 (COVID-19) pandemic response. It is important to understand the reliability of assays with different antigen or antibody targets to detect humoral immunity after SARS-CoV-2 infection and to understand how antibody (Ab) binding assays compare to those detecting neutralizing antibody (nAb), particularly as we move into the era of vaccines. Methods: We evaluated the performance of 6 commercially available enzyme-linked immunosorbent assays (ELISAs), includin..View full abstract
This work was supported by the Victorian Department of Health and Human Services and by the Australian Government Department of Health.